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Abstract
Background: The understanding of the distribution of hepatitis B virus genotypes and the occult hepatitis B virus
infection in hepatocellular carcinoma may shed light into the prevention and treatment of hepatocellular
carcinoma. The purpose of the study is to investigate hepatitis B virus genotypes distribution, the high-risk
genotypes and the occult infection in north-western China’s hepatocellular carcinoma patients.
Methods: Hepatitis B virus genotypes A-D of hepatocellular carcinoma tumor tissues and serum samples in 268
north-western China hepatocellular carcinoma patients were detected by fluorescence polarization assay. The
hepatitis B virus genotypes in serum and matched primary tumor tissue samples were compared. Hepatitis B
surface antigen and a-fetoprotein in serum were detected. Occult hepatitis B virus infections were analyzed. The
relationship between hepatitis B virus genotypes and clinicopathologic characteristics were analyzed statistically
using SPSS v.10.0.
Results: Intrahepatic hepatitis B virus DNA was detected in 83.6% of 268 patients, whereas serum hepatitis B virus
DNA was detected in 78.7%. The hepatitis B virus genotypes in serum were consistent with the results in matched
tumor tissue. Intrahepatic hepatitis B virus genotype B and C were detected respectively in 11.6% and 54.5% of the
patients. Mixed intrahepatic hepatitis B virus genotypes were detected in 13.4% of 268 patients. There was not
mixed hepatitis B virus infection in Edmondonson grade I. The patients with mixed HBV genotypes exhibited
statistically significant different Edmondson grade than the patients with single type HBV infection (p < 0.05).
Hepatitis B surface antigens were positive in 77.2% of 268 patients. Hepatitis B virus genotype C was detected in
64.7% of occult infected patients. There was no significant differences of patients’ ages and a-fetoprotein level in
different groups of intrahepatic hepatitis B virus genotypes (p > 0.05).
Conclusions: Hepatitis B virus genotype C was associated closely with the development of hepatocellular
carcinoma and the occult hepatitis B virus infection in patients in north-western China. There was a relatively high
prevalence of mixed hepatitis B virus infection in Edmondonson grade III-IV.
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Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors worldwide. Hepatitis B virus
(HBV) infection is strongly associated with the occur-
rence and development of HCC [1]. HBV can be classi-
fied into eight genotypes (designated by capital letters
A-H) based on an inter-group divergence of 8% or more
in the complete nucleotide sequence and HBV geno-
types affect the clinical course of HCC and response to
treatment. HBV genotypes have a pattern of geographi-
cal distribution. The HBV genotype A, B, C and D has
been found in China [2,3]. The understanding of the
distribution of HBV genotypes and the occult HBV
infections in HCC may shed light into the future pre-
vention and treatment of HBV-related HCC in China.
Advances in molecular biotechnology have allowed the
detailed study of the viral genotypes of HBV and the
occult HBV infections. Numerous studies have been
done on investigating the distribution and the impact of
HBV genotypes in HCC. HBV genotype C has been
found to be a higher risk factor for development of
HCC as compared with HBV genotype B in Taiwan [4].
However, the distribution of HBV genotypes, the high-
risk genotypes of HBV and the occult HBV infections in
HCC have not been investigated in north-western region
of China. In this study, HBV genotypes A-D of primary
tumor tissues and serum samples in 268 north-western
China HCC patients were detected by a simple and
cost-effective fluorescence polarization (FP) assay and
the occult HBV infections were investigated [5].
Materials and methods
Patient population, samples and DNA extraction
From January 2008 to June 2010, 268 patients with
pathologically confirmed HCC, everage age of 54.75 ±
11.69 (interquartile range, 29-76) years, 218 male
patients and 50 female patients, who underwent surgi-
cal resection or hepatic puncture in Tangdu Hospital
and Xijing Hospital of the Fourth Military Medical
University, and Xian Jiaotong University, Xian, China,
were included in this study. Primary tumor tissue sam-
ple was surgically obtained or hepatic puncture from
each patient. Areas of tumor tissue were previously
delineated for each sample by microscopic examination
of a reference slide stained with H&E. Histological
examinations were carried out and the final diagnosis
was made by pathologists. Matched tumor tissue and
serum samples were obtained from all the HCC
patients. All the patients who had not received hepati-
tis B vaccination signed informed consent to partici-
pate in this study and gave permission for the use of
their serum and tumor tissues samples. All the samples
were stored in liquid nitrogen until use. The study was
in compliance with the Helsinki Declaration and was
approved by the Human Research Protective Commit-
tee of The Fourth Military Medical University
(CNTG0801).
Hepatitis B surface antigen (HBsAg) in serum was
detected with ELISA assays (Kehua, Shanghai, China)
and a-fetoprotein (AFP) in serum was detected with
Elecsys AFP Roche Diagnostics GmbH (Roche, Switzer-
land). The patients’ clinical and pathological characteris-
tics were reported in Table 1.
Genomic DNA was extracted respectively from the
matched serum and primary tumor tissue. DNA
extracted from tumor tissue by the DNeasy Tissue Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’si n s t r u c t i o n sa n de l u t e di nT r i s - E D T Ab u f f e r
(10 mM Tris-HCl [pH 8.0] and 1 mM EDTA diso-
diumsalt), stored at -70°C. DNA extracted from
serum by the QIAamp DNA Blood Mini kit (QIA-
GEN, Hilden, Germany) following the manufacturer’s
instructions and eluted in Tris-EDTA buffer, stored at
-70°C.
All the tumor tissue samples were checked by PCR
assay using primers specific for a-tubulin to exclude the
presence of inhibitors and to assess the quality and the
integrity of the extracted DNA as described previously
[6]. All the primers and probes were synthesized and
labeled by Invitrogen (Shanghai, China).
Table 1 Intrahepatic HBV-genotypes and Clinicopathologic Characteristics
Total Grade I Grade II Grade III - IV HBsAg AFP(ng/L) Age
No.(%) 268 85(31.7%) 123(45.9%) 60(22.4%) Positive (X ± SD) (X ± SD)
HBV DNA
Positive 224 83 102 39 207 359 ± 164 54.73 ± 10.7
HBV A 1 0 1 0 0 338 ± 54 50.92 ± 6.3
HBV B 31 13 14 4 27 407 ± 163 51.71 ± 12.2
HBV C 146 69 64 13 135 368 ± 191 56.27 ± 9.3
HBV D 10 1 5 4 9 433 ± 151 54.21 ± 7.2
Mixed 36 0 18 18 36 387 ± 179 53.98 ± 11.6
HBV DNA
Negative 44 2 21 21 0 374 ± 160 58.46 ± 14.3
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Page 2 of 6HBV DNA amplification by a single asymmetric PCR
In this study, we investigated the presence of HBV
DNA genotypes A-D by the FP assay based on a single
asymmetric PCR and hybridization according to the
previously described method. The minimum level of
t h eF Pa s s a yw a s2 . 5c o p i e sa n dt h eF Pa s s a yw a sa b l e
to detect the minor population of HBV genotypes even
when their contents were as low as 1% [5]. HBV nega-
tive serum containing pGEM-T-HBV-A, pGEM-T-
HBV-B, pGEM-T-HBV-C, pGEM-T-HBV-D were
amplified as positive controls. HBV negative serum
containing pGEM-T-easy Vector DNA was amplified
as negative controls. The DNA extracted from serum
and tumor tissue of each sample with successful ampli-
fication of a-tubulin was subjected to the asymmetric
PCR. Each sample was analyzed in duplicate. A pair of
general primers (HBV-FOR 5’-tcaccatattcttgggaacaaga-
3’and HBV-REV 5’-ttcctgaactggagccacca-3’), with a
high sensitivity for the amplification of HBV genotypes
At oD ,w e r eu s e di nt h i ss t u d y .I nb r i e f ,5μlo ft h e
DNA extraction from each sample was subjected to an
asymmetric PCR. An asymmetric PCR was carried out
in 25 ul PCR reaction buffer containing 1.25 U Taq
polymerase (Promega, USA), 0.2 mM dNTP (each),
unequal amounts of the two primers (10 pmol HBV-
FOR and 80 pmol HBV-REV primers). Finally, the
reaction mixture was subjected to an additional cycle
without extension so as to generate mainly single-
stranded DNA.
Detection of HBV-genotypes by the fluorescence
polarization assay
The determination of genotypes A-D of HBV was done
simultaneously by the FP assay with four labeled geno-
type-specific probes (HBV-A-probe, HBV-B-probe,
HBV-C-probe and HBV-D-probe), according to the pre-
viously described method with modifications [5]. The
four probes hybridized with one of the strands of the
target amplicons were labeled with different fluorescent
reporter dye (TAMRA, FAM, ROX, BTR) to differenti-
ate the amplification of every HBV genotype. The asym-
metric PCR products generated from every sample were
subjected to the FP assay. In brief, 200 ul mixtures of
the four probes and 20 ul of the asymmetric PCR pro-
ducts were incubated at 48°C for 30 min. The FP values
of reaction buffer were measured using the Fluorescence
Polarization Capable Instrument (YG-06, Yangguang,
Shanxi, China) and the HBV genotypes were determined
by the increased FP values. The reaction was performed
in duplicate.
Results
HBV genotypes in serum and primary tumor tissue
samples
In this study the presence of HBV DNA genotypes in
primary HCC tumor tissue and serum samples were
d e t e c t e db yt h eF Pa s s a y( T a b l e1 ) .I n t r a h e p a t i cH B V
DNA was detected in 83.6% (224/268) of the HCC
patients, whereas intrahepatic HBV DNA was not
detected in 16.4% (44/268) of the HCC patients. Mean-
while, HBV-DNA in matched serum samples was only
detected in 79.1% (211/268) of the HCC patients. The
HBV DNA-genotypes in serum from the 211 patients
were consistent with the results in the matched primary
tumor tissue.
Among intrahepatic HBV DNA positive samples,
mixed HBV DNA-genotypes were detected in 13.4%
(36/268) of the HCC patients, 28 cases with HBV-geno-
type B and HBV-genotype C and 8 case with HBV-gen-
otype C and HBV-genotype D. HBV-genotype C(54.5%)
and B(11.5%) attributed predominantly to intrahepatic
HBV infections in the HCC patients, whereas HBV gen-
otypes A infection (0.3%) was the least observed. Distri-
bution of HBV genotypes in HCC tissues was shown in
Figure 1.
Occult HBV infection of the HCC patients
Occult HBV infection is defined by the presence of HBV
DNA in serum or liver tissue in the absence of HBsAg
[7]. In this study, HBsAg were positive in only 77.2%
(207/268) of the HCC patients. Occult HBV infections
were found in 17 HCC patients. Four HCC patients
with both serum and intrahepatic HBV-genotype C
positive were detected with HBsAg negative. Thirteen
+%9&

+%9'

0L[HG

+%9%

+%9

+%9$

+%9
+%9$
+%9%
+%9&
+%9'
0L[HG
Figure 1 Distribution of HBV genotypes in HCC tissues.
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serum HBV-DNA negative were detected with HBsAg
negative. No mixed intrahepatic HBV infection was
found in the 17 occult HBV infection HCC patients.
Distribution of HBV genotypes in HCC tissues with
occult HBV infection was shown in Figure 2.
Relation between intrahepatic HBV DNA-genotypes and
clinicopathologic characteristics
High AFP level in serum is considered as an important
clinical marker for the happening of HCC. Our study
investigated the AFP level in the HCC patients. The
potential relationship of intrahepatic HBV-genotypes,
AFP level and the patients’ ages were analyzed using
SPSS v.10.0 software (SPSS Inc., USA). There were no
statistically significant differences of the patients’ ages
and AFP level in different groups of intrahepatic HBV-
genotypes (Table 1). The prevalence of occult HBV
infection did not differ with patients’ ages and AFP level.
The potential relationship between intrahepatic HBV-
genotypes and the tumor Edmondonson grades were also
being investigated. No mixed HBV infection was found in
the patients with Edmondson grade I. There was a higher
percentage of mixed HBV infection (18/60) in Edmondon-
son grade III-IV than that (18/123) in Edmondonson
grade II. A higher percentage of patients with mixed HBV
genotypes exhibited a more severe HCC based on
Edmondson grade, this was statistically significant differ-
ent with patients of single type HBV infection (p < 0.05).
Discussion
HBV DNA was frequently found positive in HCC
patients. HBVs are able to persist in the host for years
and the continuous intrahepatic inflammation maintains
a cycle of liver cell destruction and regeneration that
often results in HCC [8]. The incidence of HCC is high
in the world, and 43% of the HCC patients reside in
China. HBV genotypes affect the clinical course of
infection and development of HCC [9]. It has been
reported that HBV genotype C and D were associated
with an increased risk of HCC compared with other
HBV genotypes, HBV genotype C and D were associated
with more severe liver diseases and rapid fibrosis devel-
opment [10]. And HCC patients with HBV genotype C
have a greater tumor recurrence rate compared with
those with HBV genotype B [11]. The differences in the
immunopathogenesis between various HBV genotypes
have been reported [12]. Detection of the HBV geno-
types in HCC would be useful for the study of the epi-
demiology and molecular mechanism of HBV in the
development of HCC. The distribution of HBV geno-
types in HCC varies in different countries and even
within different regions of the same country [13]. In
mainland China, HBV genotype C is predominant in
Beijing and Shandong and HBV genotype B in Hunan
and Fujian; whereas HBV genotype B and HBV geno-
type C are almost equally prevalent in Yunnan and
Guangdong [14]. The incidence of HBV-related HCC is
high in north-western China. Considering that HBV
genotypes A-D are predominantly in China, we detected
HBV genotypes A-D by an improved FP assay in serum
and matched primary tissue samples of the HCC
patients in north-western China. The FP assay was sim-
ple and cost-effective because HBV genotypes A-D
could be detected by a single PCR reaction [5]. This is
t h ef i r s ts t u d yt os h o wH B Vg e n o t y p e si nt h eH C C
patients in north-western China. This study showed, as
in Table 1, that intrahepatic HBV infections were attrib-
uted predominantly to HBV genotypes C and B, that
constituted 65.2% and 13.8% respectively. In addition,
there was a relatively high prevalence of mixed infec-
tions of 16.1% (36/224) in the studied group. HBV geno-
type C was found in all the mixed infections. This study
suggested that HBV-genotype C infections were the
most common causes of HCC in the patients in north-
western China.
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Figure 2 Distribution of HBV genotypes in HCC tissues with occult HBV infection.
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Page 4 of 6The diagnosis of HBV infection is usually based on
the detection of HBsAg in blood. However, HBsAg sero-
clearance does not necessarily imply HBV DNA eradica-
tion and HBsAg negative were not sufficient markers to
exclude HBV DNA carriers [15,16]. Occult HBV infec-
tion might occur after complete clinical recovery from
acute self-limited hepatitis or because of HBV DNA
mutation. HBV might be reactivated in patients with
decreased immune status undergoing anticancer che-
motherapy [17-20]. The persistent HBV infections have
a critical role in the development of HCC in HBsAg-
negative patients. Occult HBV infection might be asso-
ciated with more severe liver damage, cryptogenic
chronic hepatitis, more advanced fibrosis. Furthermore,
occult HBV infection affect responsiveness to therapy
and disease progress and the HBV genotypes influence
the frequency of occults HBV[21-26]. The incidence of
occult HBV infection is different in different countries.
Despite the importance of the occult HBV infection,
there is little information of HBV genotypes and its rela-
tion with occult infection in the HCC patients in north-
western China. In this study, occult HBV infection and
the genotypes of occult HBV infection in the HCC
patients in north-western China were investigated. In
the 268 HCC patients, occult intrahepatic HBV infection
was detected in 17 cases. The occult intrahepatic HBV
infections in the HCC patients were predominantly to
genotypes C that constituted 64.7% (11/17). Our results
revealed that occult HBV genotypes C infections were
closely related with the occurrence of HCC in north-
western China.
It is well recognized that serum is not the best source
for the detection of HBV DNA in occult HBV infection
and that the liver constitutes the most reliable source of
material. This study suggested that the detection of
HBV-DNA in primary tumor tissue has a higher sensi-
tivity than that in matched serum. Nonetheless, it was
documented that peripheral blood mononuclear cells
(PBMC) also harbour HBV DNA and its replication
intermediates and they should be considered when
detection of low levels of HBV DNA is attempted
[27,28]. HBV DNA was not detected in PBMC in this
study. The limitations of the approach would be investi-
gated in future.
Conclusions
HBV genotypes distribution and occult HBV infection in
the HCC patients in north-western China has been
investigated. The study suggested that HBV genotype C
infections were associated closely with the development
of HCC and the occult HBV infection in the HCC
patients in north-western China. There was a relatively
high prevalence of mixed infections in Edmondonson
g r a d eI I I - I Vi nt h es t u d i e dg r o u p .T h i sw o u l db eu s e f u l
for the study of the epidemiology and molecular
mechanism of HBV genotypes on HCC development
and therapy in future.
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